196 related articles for article (PubMed ID: 1919901)
61. Immunogenicity of Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine in children with sickle hemoglobinopathy or malignancies, and after systemic Haemophilus influenzae type b infection.
Kaplan SL; Duckett T; Mahoney DH; Kennedy LL; Dukes CM; Schaffer DM; Mason EO
J Pediatr; 1992 Mar; 120(3):367-70. PubMed ID: 1538281
[TBL] [Abstract][Full Text] [Related]
62. Interchangeability of Haemophilus influenzae type b vaccines in the primary series: evaluation of a two-dose mixed regimen.
Bewley KM; Schwab JG; Ballanco GA; Daum RS
Pediatrics; 1996 Nov; 98(5):898-904. PubMed ID: 8909483
[TBL] [Abstract][Full Text] [Related]
63. From the Centers for Disease Control and Prevention. Committee on immunization practices: PedvaxHIB lots with questionable immunogenicity.
JAMA; 1992 Dec; 268(22):3186. PubMed ID: 1433752
[No Abstract] [Full Text] [Related]
64. Association between immunoglobulin allotypes and immune responses to Haemophilus influenzae and Meningococcus polysaccharides.
Pandey JP; Fudenberg HH; Virella G; Kyong CU; Loadholt CB; Galbraith RM; Gotschlich EC; Parke JC
Lancet; 1979 Jan; 1(8109):190-2. PubMed ID: 84209
[TBL] [Abstract][Full Text] [Related]
65. Immune responses to polysaccharides: lessons from humans and mice.
González-Fernández A; Faro J; Fernández C
Vaccine; 2008 Jan; 26(3):292-300. PubMed ID: 18160186
[TBL] [Abstract][Full Text] [Related]
66. Antibody responses of human infants to three doses of group A Neisseria meningitidis polysaccharide vaccine administered at two, four, and six months of age.
Gold R; Lepow ML; Goldschneider I; Draper TF; Gotschlich EC
J Infect Dis; 1978 Dec; 138(6):731-5. PubMed ID: 105053
[TBL] [Abstract][Full Text] [Related]
67. Is Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) compatible with diphtheria-pertussis-tetanus vaccine in young infants?
Scheifele D; Bjornson G; Guasparini R; Meekison W
Pediatr Infect Dis J; 1993 Nov; 12(11):952-4. PubMed ID: 8265288
[No Abstract] [Full Text] [Related]
68. [When should vaccination against Haemophilus influenzae type b take place?].
Stickl HA
Med Monatsschr Pharm; 1991 Jan; 14(1):24. PubMed ID: 2017108
[No Abstract] [Full Text] [Related]
69. Immunogenicity of Haemophilus b conjugate vaccine (meningococcal protein conjugate) in children with prior invasive Haemophilus influenzae type b disease.
Walter EB; Moggio MV; Drucker RP; Wilfert CM
Pediatr Infect Dis J; 1990 Sep; 9(9):632-5. PubMed ID: 2235187
[TBL] [Abstract][Full Text] [Related]
70. [Vaccination against Haemophilus influenzae].
Huber EG
Padiatr Padol; 1991; 26(4):203-4. PubMed ID: 1749631
[No Abstract] [Full Text] [Related]
71. Vaccination responses to capsular polysaccharides of Neisseria meningitidis and Haemophilus influenzae type b in two C2-deficient sisters: alternative pathway-mediated bacterial killing and evidence for a novel type of blocking IgG.
Selander B; Käyhty H; Wedege E; Holmström E; Truedsson L; Söderström C; Sjöholm AG
J Clin Immunol; 2000 Mar; 20(2):138-49. PubMed ID: 10821465
[TBL] [Abstract][Full Text] [Related]
72. Responses of children to booster immunization with their primary conjugate Haemophilus influenzae type B vaccine or with polyribosylribitol phosphate conjugated with diphtheria toxoid.
Decker MD; Edwards KM; Bradley R; Palmer P
J Pediatr; 1993 Mar; 122(3):410-3. PubMed ID: 8441096
[TBL] [Abstract][Full Text] [Related]
73. Immunogenicity of Haemophilus influenzae type b conjugate vaccines in infant rhesus monkeys.
Vella PP; Ellis RW
Pediatr Res; 1991 Jan; 29(1):10-3. PubMed ID: 2000253
[TBL] [Abstract][Full Text] [Related]
74. Advisory Committee on Immunization Practices update: report of PedvaxHIB lots with questionable immunogenicity.
Centers for Disease Control (CDC)
MMWR Morb Mortal Wkly Rep; 1992 Nov; 41(46):878-9. PubMed ID: 1435679
[No Abstract] [Full Text] [Related]
75. Haemophilus influenzae type b-outer membrane protein complex glycoconjugate vaccine induces cytokine production by engaging human toll-like receptor 2 (TLR2) and requires the presence of TLR2 for optimal immunogenicity.
Latz E; Franko J; Golenbock DT; Schreiber JR
J Immunol; 2004 Feb; 172(4):2431-8. PubMed ID: 14764714
[TBL] [Abstract][Full Text] [Related]
76. Haemophilus b conjugate vaccines for prevention of Haemophilus influenzae type b disease among infants and children two months of age and older. Recommendations of the immunization practices advisory committee (ACIP).
MMWR Recomm Rep; 1991 Jan; 40(RR-1):1-7. PubMed ID: 1899280
[TBL] [Abstract][Full Text] [Related]
77. The biology of Haemophilus influenzae type b vaccination failure.
Holmes SJ; Granoff DM
J Infect Dis; 1992 Jun; 165 Suppl 1():S121-8. PubMed ID: 1588145
[TBL] [Abstract][Full Text] [Related]
78. National Advisory Committee on Immunization (NACI). Statement on Haemophilus influenzae type B conjugate vaccines for use in infants and children.
Can Commun Dis Rep; 1992 Dec; 18(23):169-76. PubMed ID: 1291012
[TBL] [Abstract][Full Text] [Related]
79. Immune response of young children vaccinated with Haemophilus influenzae type b conjugate vaccines.
Madore DV; Phipps DC; Eby R; Johnson CL; Smith DH
Contrib Microbiol Immunol; 1989; 10():125-50. PubMed ID: 2684505
[No Abstract] [Full Text] [Related]
80. Functional affinity of antibody to the Haemophilus influenzae type b polysaccharide.
Griswold WR; Lucas AH; Bastian JF; Garcia G
J Infect Dis; 1989 Jun; 159(6):1083-7. PubMed ID: 2786040
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
